Report says COVID-19 patients respond to Gilead's remdesivir, shares surge

8:50pm PDT - April 16th, 2020    remdesivir - Reuters

Gilead Sciences Inc's shares surged 16% in after hours trading on Thursday following a media report detailing encouraging partial data from trials of the U.S. company's experimental drug remdesivir in severe COVID-19 patients.